Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products.
版權(quán)聲明：本文版權(quán)歸FT中文網(wǎng)所有，未經(jīng)允許任何單位或個人不得轉(zhuǎn)載，復(fù)制或以任何其他方式使用本文全部或部分，侵權(quán)必究。